Feature Alcobra’s ADHD program moving to pediatrics By Len Zehr With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric... January 14, 2014